|Day Low/High||53.23 / 53.90|
|52 Wk Low/High||36.15 / 57.44|
What if the market is simply pricing in a quarter that had already been priced out?
Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?
The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
A look at those stocks likely to lead in the short- and long-term, the headlines out of China and Hong Kong, and the import of fiscal stimulus.
I have always liked the aggressive management.
The small biotech's market cap sits at $125 million, the low end of what I believe is fair.
There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.
Let's review the charts and indicators.
These pharmaceutical names have what it takes amid the current crisis and for the long run.
Fed repo policy changes confirm that external issues are having only a small impact on U.S. economic performance.
Nobody in AbbVie right now is in it for the past performance.
For those who love a roll of the dice, GNPX may be worth a closer look.
These healthcare stalwarts look attractive for growth and income.
These stocks are priced for total imperfection. That's just what you want.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...
I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...
What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?
These companies are working to plant their flag in a new landscape.
One of pharma's biggest CEO's talks M&A action on the exchange.
Both biotech stocks are at or near 52-week lows, but don't deserve to be.